Rajesh Malik - 13 Sep 2022 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Medical Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
GTHX
Transactions as of
13 Sep 2022
Transactions value $
-$275,726
Form type
4
Filing time
16 Sep 2022, 16:31:00 UTC
Previous filing
06 Jul 2022
Next filing
28 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $7,020 +18,000 +25% $0.39 91,207 13 Sep 2022 Direct
transaction GTHX Common Stock Sale -$282,745 -18,000 -20% $15.71* 73,207 13 Sep 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -18,000 -46% $0 21,439 13 Sep 2022 Common Stock 18,000 $0.39 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $15.38 and a high of $16.20. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 Represents (i) 54,332 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F4 All shares underlying this option have vested.